Bailout Watch 576: Feel the Burn
TTAC commentator Corky Boyd offers a timely analysis:
“The administration has loaned or agreed to loan a total of $65 billion to GM and Chrysler in exchange for 60 percent ownership of GM and an 8 percent stake in Chrysler.”
If the two produce 3.5 million vehicles for the year (and that’s on the high side), that’s over $17,000 per vehicle of subsidy. And that doesn’t include the $15 billion loan to GM the government forgave in the bankruptcy and the infusion Chrysler will need before the end of the year.
Last year brought the use of a new term in finance, “Cash Burn.” I guess it’s a take off on the aviation term of fuel burn. It’s a very casual term for billions of taxpayer dollars that have to be used to make up the “burn.”
More by Robert Farago
Comments
Join the conversation
"No, we can get similar results for about half the cost as demonstrate in many places. Obviously that bothers some folks so much they can’t even bring themselves to admit it’s the topic of discussion even after it’s repeated to them numerous times." What is demonstrated in many places, is: Given that the cost of drug, machinery and procedure development are already being borne by Americans, one can achieve population wide statistically equal, or in some areas perhaps even better, results than America does by piggybacking on their research, and rationing access to it in a less willy nilly fashion. In all the countries being held up as "cheaper and better", drug prices are a lot lower than here. Unsustainably low for the costs incurred in their development, were it not for American patients paying substantially more (and popping pills like it was candy). Same goes for non drug technology. Top echelon US care providers bear the early development costs, because their patients have a choice of where to go, and demand the latest and greatest when it comes to their health, costs be damned. Then, once the technology is less exotic and cheaper, care providers more concerned with system wide cost / benefit, get in on the act. Take the US out of that equation, and costs everywhere else will either have to climb; or infinitely more likely, innovation will slow, as there will be less need for care providers to compete on (perceived) quality of care by nabbing up the latest and greatest gizmos. Not that I doubt we can get equal or even better results for half the price of what we are currently paying, but we won't do so by attempting to move closer to the Soviet model, however incrementally.
So is the assumption that the drug price differential or research is a real large portion of health costs? I want to pin it down so it won't squirm into some other excuse next time. I love the attempts to weasel out of the clearly demonstrated inefficiencies in allocation through distraction. Too bad you're not talking to the usual crowd of other simpletons who can't tell the difference. Witness: but we won’t do so by attempting to move closer to the Soviet model, however incrementally Wait, shouldn't it be Al Qeada and the terrorists to jive with modern scare conventions?